SCHEMBL203231

SCHEMBL203231

Nc1nc2cnc3ccccc3c2n1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 1/20 0.50
KDM4E B2RXH2 6/20 0.44
GPR3 P46089 1/20 0.44
NCF1 P14598 1/20 0.39
PI4KA P42356 1/20 0.39
PI4K2B Q8TCG2 1/20 0.39
PI4K2A Q9BTU6 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
ADORA3 P0DMS8 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
ALDH1A1 P00352 2/20 0.38
GLA P06280 2/20 0.38
HPGD P15428 2/20 0.38
CASP1 P29466 2/20 0.38
CASP7 P55210 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 2/20 0.38
CHRM2 P08172 1/20 0.38
ADRA2A P08913 1/20 0.38
CHRM1 P11229 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5410294 0.81 KDM4E (0.43) NOS2KDM4EGPR3NCF1PI4KA
SCHEMBL18998178 0.81 KDM4E (0.54) KDM4EGPR3NCF1PI4KAPI4K2B
Hydrochloric Acid SCHEMBL4758757 0.80 KDM4E (0.53) KDM4EGPR3HSD17B10KMT2AMEN1
SCHEMBL202430 0.78 NOS2 (0.44) NOS2KDM4ETDP1ALDH1A1SMN1; SMN2
SCHEMBL4755797 0.75 SMN1; SMN2 (0.49) KDM4EADORA3ALDH1A1HPGDSMN1; SMN2
SCHEMBL1170709 0.74 TLR7 (0.49) KDM4ETDP1ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL4758349 0.74 PDE5A (0.46) KDM4EALDH1A1GLASMN1; SMN2RAB9A
SCHEMBL7570132 0.73 TLR8 (0.59) TDP1POLBHTTPDE4APDE4B
SCHEMBL7570122 0.73 ATM (0.56) ADORA3SMN1; SMN2LMNATSHRPDE4A
SCHEMBL4756005 0.72 TLR7 (0.46) NCF1GLASMN1; SMN2RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088788-B2 Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-03 US disclosed
US-8088788-B2 Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-03 US disclosed
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS PFIZER INC. 2009-09-03 US disclosed
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS PFIZER INC. 2009-09-03 US disclosed
WO-2007106852-A2 SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS IL2, IFNG, IL4 NOS2 238/4885KDM4E 2419/4885GPR3 1522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.